BGV1
Financiado
New vaccine for a paradigm shift in Brucellosis one of the world s most widespr...
New vaccine for a paradigm shift in Brucellosis one of the world s most widespread zoonotic diseases affecting humans
Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucel...
Brucellosis is the world’s most widespread zoonotic disease. It is a global problem but most severely affects poor livestock keepers in the developing world because of its impacts on human and animal health and livelihoods. Brucellosis is endemic in most of Asia, Africa and Latin America and is prevalent in the EU Mediterranean regions. Currently vaccines for Brucellosis, around since the 1950s, suffer from serious safety drawbacks mainly due to residual virulence for animals and humans. Combined with rising antibiotic resistance, their use is relatively limited.
GreenVac is developing BGV1, the first vaccine in over 60 years against Brucella melitensis in small ruminants that overcomes the main drawbacks of existing vaccines. BGV1 has been designed to a) be avirulent for animals, b) eliminate interference with diagnostic tests after vaccination, c) have low potential transmissibility to humans and, d) be treatable with standard antibiotics. BGV1 is a strong candidate to replace the classic virulent vaccine, exhibiting a safe profile with an enhanced protective efficacy, no residual virulence and minimal serodiagnostic interference.
A successful BGV1 EU-project will allow, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. The reduction of B. melitensis outbreaks and infection rate in animals will generate €3.81bn in cumulative economic benefits for users by 2029 by evading unnecessary diagnostics costs and losses caused by the infection. It will lead to a lower disease incidence in humans amidst ever rising globalisation and bioterrorism threats to anyone, anywhere. BGV1 will contribute to the objectives of the One Health Initiative: One World, One Health, One Medicine to improve the lives of all species through the integration of human medicine, veterinary medicine and environmental science.
ver más
Duración del proyecto: 36 meses
Fecha Inicio: 2020-02-20
Fecha Fin: 2023-02-28
Fecha Fin: 2023-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2023-02-28
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
BRUCELLA GREEN VAC
La fabricación y comercialización de vacunas y métodos de diagnóstico veterinario. el desarrollo de productos biotecnológicos veterinarios.
Perfil tecnológico
TRL
4-5
1M
Perfil tecnológico
TRL
4-5
1M